<DOC>
	<DOCNO>NCT00632216</DOCNO>
	<brief_summary>The study label real condition prescription Actonel investigate satisfaction patient new formulation : 35 mg Once A Week . The study also measure response rate CTX ( C-telopeptide type I collagen ) baseline 12 week treatment risedronate 35 mg Once A Week .</brief_summary>
	<brief_title>A Study Determine Satisfaction With Actonel Postmenopausal Women With Osteoporosis</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis , Postmenopausal</mesh_term>
	<mesh_term>Risedronate Sodium</mesh_term>
	<mesh_term>Etidronic Acid</mesh_term>
	<criteria>Postmenopausal outpatient woman &gt; 55 &lt; 70 year clinical presentation appropriate treatment establish osteoporosis base investigator 's clinical judgment ( Tscore BMD ( DEXA ) lumbar spine femoral neck less equal 2.5 assessment perform screen within 12 month prior screen visit evidence previous vertebral fracture ) . History Cancer : Basal Cell Squamous Cell carcinomadocumented 6month remission . Diagnosis hypocalcemia , hyperparathyroidism , hyperthyroidism . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>Female</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2008</verification_date>
</DOC>